MEK Signaling Drives T Cell Exhaustion in Cancer Immunotherapy
Cancer immunotherapy can unleash T cells to kill tumors, but these specialized cells frequently become worn down before eliminating the disease. This process, known as T cell exhaustion, leaves immune cells unable to maintain their attack or control tumor growth. Researchers at Memorial Sloan Kettering Cancer Center identified a signaling molecule called MEK as a critical driver of this exhaustion. Santosha Vardhana, MD, PhD, a physician-scientist at the center, notes that for some patients, immunotherapy seems to work initially but then fades, leaving them with a brief wisp of promise only to have it taken away
.
Excessive MEK activity drives cells into complete burnout
Scientists previously viewed T cell exhaustion as a simple loss of cellular function. Work from the Memorial Sloan Kettering laboratory revealed that exhausted T cells remain highly active and consume significant resources. Excessive MEK activity eventually drives T cells toward complete burnout.
Blocking signaling reduces pressure on cells to manufacture proteins
Blocking MEK signaling reduces the pressure on T cells to continuously manufacture cytotoxic proteins, allowing some cells to persist. Inhibiting MEK makes cells more conservative, helping them live longer while reducing their immediate cancer-killing rate.
Targeting Treatment Based on Tumor Size and Immune Response
MEK inhibitors require selective application depending on individual patient characteristics. Patients with small tumors and high numbers of immune cells do not require T cell conservation, as traditional immunotherapy typically succeeds in these cases. Conversely, patients with large tumors or few tumor-fighting immune cells may benefit from a slower, sustained response enabled by a MEK inhibitor. Potential applications include checkpoint inhibitors and tumor-infiltrating lymphocyte therapy. Dr. Vardhana noted that because FDA-approved MEK inhibitors already exist, this method could be tested in humans without much delay.
Cholesterol Metabolism in Head and Neck Tumors
Separate research in China investigated which cells inside head and neck tumors burn LDL cholesterol. Using single-cell RNA sequencing, researchers found the highest LDL metabolic activity was not in cancer cells, but in the myeloid compartment, which includes dendritic cells, monocytes, and macrophages. Macrophages were the most active population. Correlation analyses showed that ITGA5 expression tracks with cholesterol metabolism genes such as SOAT1, SQLE, and LDLR. In an independent cohort, patients with a high-risk score based on this metabolic reprogramming responded more poorly to immune checkpoint blockade.
Frequently Asked Questions
What causes T cells to become exhausted during cancer treatment?
The signaling molecule MEK regulates the production of cytotoxic proteins, and excessive MEK activity drives the cells into exhaustion.
How do MEK inhibitors help preserve immune cells?
MEK inhibitors reduce the energy demand on T cells by lowering their rate of protein production. This conservative state helps the cells survive longer and persist in difficult tumor environments.
Which patients are most likely to benefit from MEK inhibition?
Patients with large tumors or relatively few tumor-fighting immune cells may benefit from the sustained, longer-lasting response provided by MEK inhibition. Patients with small tumors and high immune cell counts generally do not require this approach.
What additional therapies might be enhanced by MEK inhibition?
Researchers suggest MEK inhibition could improve checkpoint inhibitors and tumor-infiltrating lymphocyte therapy. Additional authors on the study include Jahan Rahman, Madeline Hwee, Yan-Ting Chen, Ruben Jose Jesus Faustino Ramos, Hui Liu, Travis Hartman, Justin Cross, Miguel de Jesus, Morgan Huse, Valerie Longo, and Pat Zanzonico.
Keep reading